NCT05227378View on ClinicalTrials.gov

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer

NAUnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

August 31, 2025

Conditions
Gastric Cancer
Interventions
BIOLOGICAL

neoantigen tumor vaccine with or without PD-1/L1

personalized neoantigen tumor vaccine with or without PD-1/L1

Trial Locations (1)

Unknown

Department of GI Oncology, Peking University Cancer Hospital,, Beijing

Sponsors

Collaborators (1)

NeoCura
All Listed Sponsors
collaborator

NeoCura

INDUSTRY

lead

Shen Lin

OTHER

NCT05227378 - Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter